Carl Zeiss Meditec (ETR:AFX) has been assigned a €55.00 ($63.95) target price by HSBC in a research note issued on Friday. The brokerage currently has a “neutral” rating on the stock. HSBC’s price target indicates a potential downside of 6.70% from the stock’s previous close.
Several other research firms have also recently weighed in on AFX. Nord/LB set a €60.00 ($69.77) price target on Carl Zeiss Meditec and gave the company a “neutral” rating in a report on Thursday. DZ Bank reaffirmed a “sell” rating on shares of Carl Zeiss Meditec in a report on Thursday. Hauck & Aufhaeuser set a €62.50 ($72.67) price target on Carl Zeiss Meditec and gave the company a “neutral” rating in a report on Friday, May 11th. Commerzbank set a €51.00 ($59.30) price target on Carl Zeiss Meditec and gave the company a “neutral” rating in a report on Monday, May 21st. Finally, Independent Research set a €58.00 ($67.44) price objective on Carl Zeiss Meditec and gave the company a “neutral” rating in a report on Wednesday, May 16th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. Carl Zeiss Meditec presently has a consensus rating of “Hold” and a consensus price target of €55.11 ($64.08).
ETR:AFX opened at €58.95 ($68.55) on Friday. Carl Zeiss Meditec has a twelve month low of €37.53 ($43.64) and a twelve month high of €55.25 ($64.24).
Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates through two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery.
Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.